Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Andra AP fonden

Andra AP fonden decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 19.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 321,800 shares of the biopharmaceutical company’s stock after selling 76,700 shares during the quarter. Andra AP fonden’s holdings in Gilead Sciences were worth $29,725,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in GILD. Destination Wealth Management acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $362,000. Ashton Thomas Private Wealth LLC raised its position in shares of Gilead Sciences by 2.2% during the 4th quarter. Ashton Thomas Private Wealth LLC now owns 44,217 shares of the biopharmaceutical company’s stock worth $4,084,000 after purchasing an additional 932 shares during the last quarter. Callan Family Office LLC purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $2,825,000. Hartford Funds Management Co LLC purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $548,000. Finally, E Fund Management Co. Ltd. grew its stake in shares of Gilead Sciences by 10.4% during the 4th quarter. E Fund Management Co. Ltd. now owns 31,774 shares of the biopharmaceutical company’s stock valued at $2,935,000 after buying an additional 3,000 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $116.04 on Friday. The company has a market cap of $144.62 billion, a PE ratio of 313.62, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $117.39. The business has a 50 day moving average price of $99.15 and a 200-day moving average price of $91.09. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.72%. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 293,356 shares of company stock worth $29,166,240 over the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of several research reports. Bank of America boosted their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research note on Wednesday. UBS Group raised their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Barclays lifted their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, Truist Financial lifted their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $104.24.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.